Mumbai: Glenmark Pharmaceuticals
has inked a decade long marketing and distribution agreement with MeyerZall Laboratories.
through Glenmark Pharmaceuticals South Africa, the deal will help the expansion
of the company''s product portfolio in the topical dermatology segment, and covers
therapeutic areas such as psoriasis, fungal infections of the skin and inflammation.
products with patented delivery systems such as Linotar Gel1, Covarex and Athru-Derm
will come under Glenmark''s wing, alongside its existing range of derma products
that spans Synalar, Synalar-C, Synalar-N and Naseptin.
had acquired Bouwer Bartlett Pty Ltd in December 2005, a South African sales and
marketing company. The acquisition was implemented through Glenmark''s wholly-owned
to Glenmark, it is one of the leading players in the Indian dermatology segment,
with its Candid B featuring among the top 300 pharmaceutical products in the country.